Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Thomas Höchtl"'
Autor:
Kurt Huber, Thomas Höchtl
Publikováno v:
Hämostaseologie. 34:20-28
SummaryAntiplatelet therapy in acute coronary syndromes is essential for preventing stent thrombosis and for reducing major adverse cardiovascular events. Treatment strategy has changed over the last years by frequent use of more active agents inhibi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa74bda909c94b042175848ea697636a
https://doi.org/10.5482/hamo-13-08-0044
https://doi.org/10.5482/hamo-13-08-0044
Autor:
Dominik F. Draxler, Thomas Höchtl, Matthias K. Freynhofer, G. Jakl-Kotauschek, Cihan Ay, Susanne C. Gruber, I. Pabinger-Fasching, Johann Wojta, Barbara Fellner, Veronika Bruno, Kurt Huber
Publikováno v:
Journal of Thrombosis and Haemostasis. 11:1069-1077
Summary Background Atrial fibrillation (AF) is associated with raised levels of P-selectin and an apparent prothrombotic state. However, levels of tissue plasminogen activator (t-PA)-antigen are increased also. We investigated whether high levels of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3625e0ecf37a1bbaee8afa6b79f9d196
https://doi.org/10.1111/jth.12213
https://doi.org/10.1111/jth.12213
Publikováno v:
Der Anaesthesist. 61:483-496
Akutes Koronarsyndrom (ACS) und perkutane koronare Intervention (PCI) bedurfen einer dualen Antiplattchentherapie (DAT) mit Aspirin und einem P2Y12-Rezeptor-Hemmer. Die Therapie mit Aspirin soll lebenslang durchgefuhrt werden. Die empfohlene Dauer de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e7e732accc0c39cb72d5bb16036664dc
https://doi.org/10.1007/s00101-012-2041-1
https://doi.org/10.1007/s00101-012-2041-1
Publikováno v:
CME. 9:7-14
Antikoagulanzien werden standardmasig bei Patienten mit akutem Koronarsyndrom oder Vorhofflimmern eingesetzt. In den letzten Jahren wurden zahlreiche neue Substanzen entwickelt und in klinischen Studien uberpruft. Das Paradigma lautet dabei, dass die
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b0bbc1696c26da07ea93014ae3afa752
https://doi.org/10.1007/s11298-012-1238-6
https://doi.org/10.1007/s11298-012-1238-6
Publikováno v:
European Heart Journal: Acute Cardiovascular Care. 1:87-93
Despite tremendous progress in the management of patients with an acute coronary syndrome (ACS), morbidity and mortality remains high even in stable patients after discharge. The benefit of adding vitamin K antagonists (VKA) on top of antiplatelet th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fae329ce11f94de1f170bbd20a387305
https://doi.org/10.1177/2048872612442914
https://doi.org/10.1177/2048872612442914
Publikováno v:
European Heart Journal: Acute Cardiovascular Care. 1:79-86
Dual antiplatelet therapy (DAPT), usually consisting of clopidogrel and acetylsalicylic acid (ASA), has come into discussion in recent years due to an increasing number of major adverse cardiac events based on insufficient ADP-mediated platelet inhib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f803c99cd6dc18e7421af8a062203d2e
https://doi.org/10.1177/2048872612443345
https://doi.org/10.1177/2048872612443345
Autor:
Thomas Höchtl, Kurt Huber
Publikováno v:
Fundamental & Clinical Pharmacology. 26:47-53
Oral anticoagulation in atrial fibrillation is obligatory to lower the risk of spontaneous cerebrovascular and systemic thromboembolism. For this purpose, vitamin K antagonists (coumarins) have been recommended as the most effective drugs for a long
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cd764f972f1e7e15d5bddef6795d5bea
https://doi.org/10.1111/j.1472-8206.2011.00982.x
https://doi.org/10.1111/j.1472-8206.2011.00982.x
Publikováno v:
Fundamental & Clinical Pharmacology. 26:2-10
Antiplatelet therapy is obligatory in patients with coronary artery disease (CAD) both in acute coronary syndromes (ACS) and in secondary prevention. Aspirin in combination with clopidogrel has been recommended as the main therapeutic regimen for man
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fcd52350568d982353c5b72302935224
https://doi.org/10.1111/j.1472-8206.2011.00985.x
https://doi.org/10.1111/j.1472-8206.2011.00985.x
Autor:
Paulo Caramori, Mariusz Kruk, Sandra A. Forman, Eric A. Cohen, Camille A. Pearte, Bartosz Bychowiec, Zygmunt Sadowski, James E. Udelson, José Antonio Marin-Neto, Christopher Adlbrecht, Carey Kimmelstiel, Gervasio A. Lamas, Judith S. Hochman, Witold Rużyłło, Debra Kinan, Anna Teresińska, Joseph A. Kufera, Benita Busz-Papiez, Thomas Höchtl
Publikováno v:
Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual)
Universidade de São Paulo (USP)
instacron:USP
Universidade de São Paulo (USP)
instacron:USP
Background The Occluded Artery Trial (OAT) showed no difference in outcomes between percutaneous coronary intervention (PCI) versus optimal medical therapy (MED) in patients with persistent total occlusion of the infarct-related artery 3 to 28 days p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a020a3bd7e2f8f9d79e5f223631b58f
https://doi.org/10.1016/j.ahj.2010.11.020
https://doi.org/10.1016/j.ahj.2010.11.020
Autor:
Veronika Bruno, Thomas Höchtl, Rudolf Jarai, Susanne C. Gruber, Serdar Farhan, Ivan Brozovic, Kurt Huber, Johann Wojta, Matthias K. Freynhofer
Publikováno v:
Thrombosis and Haemostasis. 105:435-443
SummaryVon Willebrand factor (vWF) plays an essential role in platelet adhesion and thrombus formation. Patients with atrial fibrillation (AF) exhibit higher plasma vWF and lower ADAMTS13 antigen levels compared to controls. Little is known about vWF
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82079c38d5d8e77b0626c7b9f4d93e1b
https://doi.org/10.1160/th10-09-0615
https://doi.org/10.1160/th10-09-0615